Sana Biotechnology Inc. (SANA)
NASDAQ: SANA
· Real-Time Price · USD
1.72
-0.15 (-8.02%)
At close: May 06, 2025, 3:59 PM
1.75
2.03%
After-hours: May 06, 2025, 07:53 PM EDT
-8.02% (1D)
| Bid | 1.35 |
| Market Cap | 386.69M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -266.76M |
| EPS (ttm) | -1.16 |
| PE Ratio (ttm) | -1.48 |
| Forward PE | -2.18 |
| Analyst | Buy |
| Ask | 1.75 |
| Volume | 2,633,236 |
| Avg. Volume (20D) | 3,330,123 |
| Open | 1.86 |
| Previous Close | 1.87 |
| Day's Range | 1.69 - 1.89 |
| 52-Week Range | 1.26 - 10.23 |
| Beta | 1.75 |
About SANA
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin ...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 4, 2021
Employees 194
Stock Exchange NASDAQ
Ticker Symbol SANA
Website https://www.sana.com
Analyst Forecast
According to 6 analyst ratings, the average rating for SANA stock is "Buy." The 12-month stock price forecast is $9, which is an increase of 424.78% from the latest price.
Stock Forecasts1 month ago
-17.69%
Sana Biotechnology shares are trading lower. The c...
Unlock content with
Pro Subscription
3 months ago
+160.61%
Sana Biotechnology shares are trading higher after the company on Tuesday announced clinical trial results from its type 1 diabetes study of islet cell transplantation without immunosuppression.
